Equities analysts predict that CryoPort Inc (NASDAQ:CYRX) will report $3.67 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for CryoPort’s earnings, with the highest sales estimate coming in at $3.93 million and the lowest estimate coming in at $3.40 million. CryoPort posted sales of $2.71 million during the same quarter last year, which suggests a positive year over year growth rate of 35.4%. The business is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that CryoPort will report full-year sales of $3.67 million for the current fiscal year, with estimates ranging from $18.00 million to $19.68 million. For the next year, analysts expect that the firm will post sales of $36.73 million per share, with estimates ranging from $33.02 million to $40.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover CryoPort.
CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, March 6th. The consumer goods maker reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $3.33 million during the quarter, compared to analysts’ expectations of $3.37 million. CryoPort had a negative net margin of 66.09% and a negative return on equity of 47.36%. The business’s revenue for the quarter was up 49.5% on a year-over-year basis.
A number of research analysts have issued reports on CYRX shares. Roth Capital started coverage on shares of CryoPort in a report on Thursday, November 30th. They issued a “buy” rating and a $12.50 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price (up from $10.00) on shares of CryoPort in a report on Thursday, March 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $33.70.
CryoPort (CYRX) traded up $0.30 during trading hours on Wednesday, reaching $10.17. 405,014 shares of the company’s stock were exchanged, compared to its average volume of 140,692. The stock has a market cap of $269.85, a price-to-earnings ratio of -29.06 and a beta of 0.71. CryoPort has a 52 week low of $1.96 and a 52 week high of $10.40.
In other CryoPort news, CEO Jerrell Shelton sold 29,257 shares of the company’s stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $9.83, for a total value of $287,596.31. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 9.00% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in CYRX. Northern Trust Corp lifted its holdings in shares of CryoPort by 105.0% during the 2nd quarter. Northern Trust Corp now owns 22,179 shares of the consumer goods maker’s stock worth $109,000 after acquiring an additional 11,358 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CryoPort during the 3rd quarter worth about $118,000. Bank of Montreal Can purchased a new position in shares of CryoPort during the 4th quarter worth about $142,000. Goldman Sachs Group Inc. purchased a new position in shares of CryoPort during the 4th quarter worth about $155,000. Finally, Monashee Investment Management LLC purchased a new position in shares of CryoPort during the 4th quarter worth about $192,000. Institutional investors and hedge funds own 22.83% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “$3.67 Million in Sales Expected for CryoPort Inc (CYRX) This Quarter” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/09/3-67-million-in-sales-expected-for-cryoport-inc-cyrx-this-quarter.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Get a free copy of the Zacks research report on CryoPort (CYRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.